Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(11):772-774; doi:10.1093/jnci/95.11.772
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 11, 772-774, June 4, 2003
© 2003 Oxford University Press

NEWS

Researchers Push for Publication, Registration of All Clinical Trials

Tom Reynolds

The first 150 words of the full text of this article appear below.

Underreporting of clinical trials in journals and registries is undermining the progress of medical science and breaching an ethical obligation to patients, advocates of evidence-based medicine warn.

Despite the time, effort, and cost involved in performing trials, and the implicit contract that assures participants they are helping advance knowledge, the results of many trials are never published in peer-reviewed journals. In addition, clinical trial registries—potentially a comprehensive source of information about ongoing and completed trials—are incomplete and inconsistent, particularly for industry-sponsored trials.

Critics have pointed fingers at drug companies’ protection of commercial interests, journal editors’ bias in favor of studies with positive or newsworthy results, and investigators’ lack of time and interest. Whatever the cause, some experts agree that simple measures could help. Research ethics committees (RECs), they say, should require registration at the outset and publication at the conclusion—and sponsors should require publication as part of the agreements with . . . [Full Text of this Article]

Publication Bias

Trial Registries


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
V. Cappelletti, L. Celio, E. Bajetta, A. Allevi, R. Longarini, P. Miodini, R. Villa, A. Fabbri, L. Mariani, R. Giovanazzi, et al.
Prospective evaluation of estrogen receptor-{beta} in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients
Endocr. Relat. Cancer, December 1, 2004; 11(4): 761 - 770.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
K. Dickersin and D. Rennie
Registering Clinical Trials
JAMA, July 23, 2003; 290(4): 516 - 523.
[Abstract] [Full Text] [PDF]